Eli Lilly’s weight-management franchise has become a primary growth engine, with tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for obesity—delivering blockbuster results. Through the first nine months of 2025, tirzepatide generated $24.8 billion in revenue, overtaking Keytruda to become the world’s best-selling medicine. Analysts forecast sales could reach nearly $62 billion by 2030, driven by new approvals such as obstructive sleep apnea and broader obesity indications. This sustained demand underpins Eli Lilly’s near-term financial outlook and positions the company to capture leading market share in the multi-billion-dollar weight-loss segment.

After surpassing a $1 trillion market capitalization in 2024, Eli Lilly’s financial trajectory remains strong despite some recent stock-price volatility. The company’s gross margin stood at 83% in the latest quarter, reflecting operational efficiency and pricing power. Revenue growth continues to outpace the broader healthcare sector, supported by both legacy products and the tirzepatide franchise. Management guidance indicates mid-teens percentage sales growth for fiscal 2026, with operating cash flow expected to exceed $18 billion, reinforcing capacity for reinvestment in R&D and shareholder returns.

Eli Lilly’s late-stage pipeline features several high-potential candidates that could extend its leadership in metabolic and obesity therapeutics. Oral orforglipron, an investigational GLP-1/glucagon receptor dual agonist, completed phase 3 studies last year and benefits from a priority review voucher that may yield FDA approval by end of February 2026. Retatrutide, a triple-agonist in phase 3, demonstrated a mean weight loss of 28.7% at the highest dose—unprecedented in obesity trials. These clinical milestones, combined with additional biopharma collaborations, underscore a robust innovation engine that should sustain growth beyond tirzepatide’s patent life.

Eli Lilly trades at approximately 33 times forward earnings, compared with a 18.2× average for the healthcare sector, reflecting investor confidence in its long-term growth runway. The company’s price/earnings-to-growth (PEG) ratio stands at 0.98, which remains below levels typically considered overvalued. Given consensus projections for double-digit earnings growth through 2028 and a high-margin product mix, the premium valuation appears warranted. For investors seeking exposure to durable revenue streams, strong cash generation, and a leading pipeline in weight-management and metabolic diseases, Eli Lilly presents a compelling risk-reward profile for 2026 and beyond.